Natera, Inc. $NTRA Shares Bought by SWS Partners

SWS Partners grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 11.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,037 shares of the medical research company’s stock after buying an additional 4,980 shares during the quarter. Natera comprises 1.8% of SWS Partners’ investment portfolio, making the stock its 12th biggest holding. SWS Partners’ holdings in Natera were worth $7,572,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. lifted its holdings in Natera by 23.1% in the third quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 81 shares during the period. CWM LLC increased its holdings in shares of Natera by 72.2% in the 3rd quarter. CWM LLC now owns 70,925 shares of the medical research company’s stock valued at $11,417,000 after purchasing an additional 29,740 shares in the last quarter. Swedbank AB increased its holdings in shares of Natera by 7.3% in the 3rd quarter. Swedbank AB now owns 45,170 shares of the medical research company’s stock valued at $7,271,000 after purchasing an additional 3,090 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in shares of Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock valued at $1,373,000 after purchasing an additional 5,614 shares during the period. Finally, Yousif Capital Management LLC boosted its holdings in Natera by 4.5% during the third quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company’s stock worth $271,000 after buying an additional 72 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on NTRA. BNP Paribas raised shares of Natera to a “hold” rating and set a $172.00 target price for the company in a report on Monday, October 27th. BTIG Research raised their price objective on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Barclays lifted their price objective on Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Stephens upped their target price on Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Fifteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $231.18.

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 4,692 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $230.76, for a total transaction of $1,082,725.92. Following the sale, the insider owned 113,065 shares in the company, valued at approximately $26,090,879.40. This trade represents a 3.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 4,400 shares of Natera stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $238.07, for a total transaction of $1,047,508.00. Following the completion of the sale, the chief executive officer directly owned 140,416 shares of the company’s stock, valued at $33,428,837.12. The trade was a 3.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 365,164 shares of company stock valued at $76,621,909. Corporate insiders own 5.63% of the company’s stock.

Natera Stock Performance

Natera stock opened at $233.74 on Friday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $246.90. The company has a market capitalization of $32.33 billion, a price-to-earnings ratio of -102.07 and a beta of 1.63. The stock has a fifty day moving average of $218.14 and a two-hundred day moving average of $181.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period in the previous year, the business earned ($0.26) EPS. The firm’s revenue was up 34.7% on a year-over-year basis. On average, analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.